Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Galera Therapeutics, Inc.GRTX · Entity 15899 | Chief Financial Officer | March 13, 2023 | March 14, 2023 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Chief Financial Officer | October 08, 2026 | October 09, 2026 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Chief Financial Officer | February 28, 2019 | March 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Galera Therapeutics, Inc.
Report date March 13, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2023-03-13 transaction · row 1
1 source rowRow 1 · 2023-03-13 · Purchase · Acquired 10,000 · Balance 10,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.95 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.95 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
UroGen Pharma Ltd.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 4,561 |
Ending reported balance
After 2026-10-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-08 · Exercise / conversion · Acquired 4,483 · Balance 6,763 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2026-10-08 · Sale · Disposed 2,202 · Balance 4,561 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,484 |
Reported balance
After 2026-10-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-08 · Exercise / conversion · Disposed 4,483 · Balance 4,484 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025.
Verrica Pharmaceuticals Inc.
Report date February 28, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.32 · Expires 2029-02-27 | Direct | 44,000 |
Reported balance
After 2019-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-28 · Grant · Acquired 44,000 · Balance 44,000 F1: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2026 Filed Oct 9, 2026 16:57 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 4,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-032421 · rdgdoc.xml · derivative · entry 3 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,484 Underlying: Ordinary Shares · 4,483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025. F3 · derivative.expiration_date: The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025. Read SEC document |
| October 08, 2026 Filed Oct 9, 2026 16:57 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 2,202 | $36.69 | $80,791.38 |
DisclosureSEC source: 0001437749-26-032421 · rdgdoc.xml · nonDerivative · entry 2 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,561 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| October 08, 2026 Filed Oct 9, 2026 16:57 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 4,483 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-032421 · rdgdoc.xml · nonDerivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 22:16 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 32,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-002841 · rdgdoc.xml · derivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,609 Underlying: Ordinary Shares · 32,609 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. F2 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 17:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 4,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030772 · rdgdoc.xml · derivative · entry 3 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,967 Underlying: Ordinary Shares · 4,483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025. F3 · derivative.expiration_date: The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025. Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 17:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 2,203 | $16.85 | $37,120.55 |
DisclosureSEC source: 0001437749-25-030772 · rdgdoc.xml · nonDerivative · entry 2 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,280 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 17:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 4,483 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-030772 · rdgdoc.xml · nonDerivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| October 08, 2024 Filed Oct 9, 2024 20:22 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantEmployee Stock Option (right to buy) · Derivative | 74,142 | $0.00 Strike: $13.11 | $0.00 |
DisclosureSEC source: 0001415889-24-024932 · form4-10092024_081051.xml · derivative · entry 2 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,142 Underlying: Ordinary Shares · 74,142 shares Expires 2034-10-08 F3 · derivative.exercise_date: 1/3 of the shares underlying the stock option will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027. Read SEC document |
| October 08, 2024 Filed Oct 9, 2024 20:22 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 13,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024932 · form4-10092024_081051.xml · derivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,450 Underlying: Ordinary Shares · 13,450 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027. F2 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 12:30 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | PurchaseCommon Stock | 10,000 | $1.96 | $19,593.00 |
DisclosureSEC source: 0000899243-23-008288 · doc4.xml · nonDerivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.95 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 23:57 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 185,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-23-006470 · doc4.xml · derivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2033-02-24 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-22-008583 · doc4.xml · derivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-02-27 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 28, 2022. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $11.99 | $0.00 |
DisclosureSEC source: 0000899243-21-003614 · doc4.xml · derivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2031-01-25 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 26, 2021. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 23:02 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 74,435 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0000899243-20-002869 · doc4.xml · derivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,435 Underlying: Common Stock · 74,435 shares Expires 2030-01-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 31, 2020. Read SEC document |
| November 06, 2019 Filed Nov 9, 2019 00:19 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option · Derivative | 229,513 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0000899243-19-027034 · doc4.xml · derivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,513 Underlying: Common Stock · 229,513 shares Expires 2029-11-05 F1 · derivative.exercise_date: The options vests and becomes exercisable with respect to 25% on October 21, 2020 with the remaining shares vesting and becoming exercisable in equal monthly installments over a three year period thereafter. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:30 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-19-015811 · doc4.xml · derivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| June 19, 2018 Filed Aug 15, 2018 20:47 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001209191-18-046825 · doc4.xml · nonDerivative · entry 1 Degnan Chris · CIK 0001741968 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.